Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Ulipristal acetate
As low as
170
CHF
CHF 170.00
In stock
Only %1 left
CDX-U0027-M05050 mgCHF 170.00
CDX-U0027-M100100 mgCHF 285.00
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | (11β)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione; CDB-2914; HRP 2000; RU 44675 |
| Product Type | Chemical |
| Properties | |
| Formula | C30H37NO4 |
| MW | 475.62 |
| CAS | 126784-99-4 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to light yellow crystalline powder. |
| Solubility | Soluble in DMSO (30mg/ml), ethanol (30mg/ml) or DMF (30mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | OOLLAFOLCSJHRE-ZHAKMVSLSA-N |
| Smiles | O=C1CCC2=C3[C@@]([C@@](CC[C@]4(OC(C)=O)C(C)=O)([H])[C@]4(C)C[C@]3([H])C5=CC=C(N(C)C)C=C5)([H])CCC2=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Scientific Background Information
Product Description
Ulipristal acetate is a selective progesterone receptor modulator (SPRM) that binds to the human progesterone receptors PR-A and PR-B (EC50s=8.5 and 7.7nM, respectively), rabbit uterine PR (EC50=13.6nM), and rabbit thymic glucocorticoid receptor (GR; EC50=15.4nM). It is selective for human progesterone receptors over the human estrogen receptor (ER; EC50>10,000nM). It inhibits growth of IGROV-1 and SKOV3 human ovarian cancer cells (IC50s=15.5 and 31.5μM, respectively) even after resistance to combined cisplatin and paclitaxel treatment has developed. Ulipristal acetate reverses the proliferative effect of progesterone on patient-derived germline mutant BRCA1 breast tissue xenografts in ovariectomized athymic mice. Formulations containing ulipristal acetate have been used as emergency contraceptives and to treat uterine fibroids.
Product-specific References
(1) B.J. Attardi, et al.; J. Steroid Biochem. Mol. Biol. 88, 277 (2004) | (2) P.A. Orihuela; Curr. Opin. Investig. Drugs 8, 859 (2007) (Review) | (3) K. McKeage & J.D. Croxtall; Drugs 71, 935 (2011) (Review) | (4) B. Mozzanega, et al.; Trends Pharmacol. Sci. 34, 195 (2013) | (5) S. Nallasamy, et al.; Reprod. Sci. 20, 371 (2013) | (6) C.D. Gamarra-Luques, et al.; J. Ovarian Res. 7, 45 (2014) | (7) N. Esber, et al.; PLoS One 10, e0140795 (2015) | (8) L. Communcal, et al.; Oncotarget 7, 45317 (2016)